Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists

US7141575B2 · kind B2 · utility

Assignee

• Vernalis Research Limited · GB

Inventors

• Roger John Gillespie · Wokingham, GB
• Joanne Lerpiniere · Wokingham, GB
• Suneel Gaur · Wokingham, GB
• Samantha Jayne Bamford · Wokingham, GB
• Gemma Caroline Stratton · Wokingham, GB
• Stefania Leonardi · Woodstock, GB
• Scott Murray Weiss · Wokingham, GB

Key dates

• Filing date: Jan 10, 2002
• Grant date: Nov 28, 2006
• Expiry date: May 15, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The use of a compound of formula (I): wherein R1 is selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4CONR5, NR4CONR5R6,NR4CO2R7 and NR4SO2R7; R2 is selected from aryl attached via an unsaturated carbon; R3 is selected from H, alkyl, COR5, CO2R7, CONR5R6, CONR4NR5R6 and SO2R7; R4, R5 and R6 are independently selected from H, alkyl and aryl or where R5 and R6 are in an NR5R6 group, R5 and R6 may be linked to form a heterocyclic group, or where R4, R5 and R6 are in a (CONR4NR5R6) group, R4 and R5 may be linked to form a heterocyclic group; and R7 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se